ETON
Eton Pharmaceuticals Inc
59.50$
+7.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.7% | -3.0% | +3.3% | +12.6% | +112.4% | +10.4% | +21.0% | +2.8% | -11.9% | +6.1% | +18.5% | |
| – | -1.2% | -9.6% | +4.8% | +17.0% | +37.9% | +21.8% | +37.0% | +5.2% | -15.9% | -12.1% | +28.8% | |
| – | -3.1% | -22.1% | +6.2% | +14.5% | -26.3% | +16.6% | +45.7% | +46.3% | -30.1% | -24.2% | +36.5% | |
| – | -3.1% | -22.1% | +6.2% | +14.5% | -26.3% | +16.6% | +45.7% | +46.3% | -30.1% | -24.2% | +36.5% | |
| – | -2.4% | +24.3% | +14.9% | +14.7% | -4.1% | +205.9% | -11.9% | -9.5% | -10.1% | +14.0% | +85.6% | |
| – | -13.3% | +154.4% | -10.8% | -6.3% | +686.0% | -10.6% | +74.7% | -29.2% | -8.5% | -6.2% | -29.9% | |
| – | +12.6% | +34.8% | -4.2% | -4.4% | +495.8% | -2.9% | -3.0% | -3.0% | -3.1% | +41.6% | +4.4% | |
| – | +11.1% | -5.9% | +20.0% | +8.2% | +160.3% | +15.3% | +30.4% | +4.7% | -19.0% | +1.7% | +3.2% | |
| – | +56.3% | -5.8% | +19.1% | +8.3% | +1.1% | +27.1% | +52.3% | +14.5% | -12.9% | +14.8% | +2.1% | |
| – | +252.8% | -6.0% | -7.3% | -11.2% | -98.2% | +1.3% | +3,496.1% | +0.3% | +216.6% | +34.3% | -25.3% | |
| – | +7.9% | +22.5% | -5.7% | +25.8% | +55.3% | +16.9% | +149.2% | +17.4% | -23.0% | +22.9% | +6.8% | |
| – | – | – | – | – | – | +0.6% | -8.6% | +0.7% | -21.1% | -13.0% | +0.7% | |
| – | -8.4% | +0.1% | -13.1% | +18.7% | +52.9% | +0.1% | -2.0% | -3.5% | +13.1% | +17.1% | +52.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +0.1% | +0.1% | +3.0% | -1.6% | +2.9% | +0.0% | +0.0% | +0.1% | +17.2% | +3.9% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.